Edition:
India

Reata Pharmaceuticals Inc (RETA.OQ)

RETA.OQ on NASDAQ Stock Exchange Global Market

168.81USD
11:55pm IST
Change (% chg)

$10.89 (+6.90%)
Prev Close
$157.92
Open
$158.68
Day's High
$168.82
Day's Low
$152.09
Volume
352,030
Avg. Vol
99,559
52-wk High
$168.82
52-wk Low
$47.50

Latest Key Developments (Source: Significant Developments)

Reata Pharmaceuticals Reacquires Rights From Abbvie To Develop And Commercialize Bardoxolone Methyl, Omaveloxolone, And All Next-Generation Nrf2 Activators
Thursday, 10 Oct 2019 

Oct 10 (Reuters) - Reata Pharmaceuticals Inc ::REATA PHARMACEUTICALS REACQUIRES RIGHTS FROM ABBVIE TO DEVELOP AND COMMERCIALIZE BARDOXOLONE METHYL, OMAVELOXOLONE, AND ALL NEXT-GENERATION NRF2 ACTIVATORS.REATA PHARMACEUTICALS INC - ABBVIE WILL RECEIVE A TOTAL OF $330 MILLION IN CASH, PRIMARILY FOR RIGHTS TO BARDOXOLONE.REATA PHARMACEUTICALS INC - REATA WILL MAKE AN UPFRONT PAYMENT OF $75 MILLION IN 2019.REATA PHARMA- ABBVIE WILL RECEIVE LOW SINGLE-DIGIT, TIERED ROYALTIES FROM WORLDWIDE SALES OF OMAVELOXOLONE AND CERTAIN NEXT-GENERATION NRF2 ACTIVATORS.REATA PHARMACEUTICALS - REATA HAS ALSO ENTERED INTO AN AMENDMENT TO ITS LOAN AND SECURITY AGREEMENT WITH OXFORD FINANCE LLC AND SILICON VALLEY BANK.REATA PHARMACEUTICALS INC - ABBVIE WILL NOT RECEIVE ROYALTIES ON BARDOXOLONE.REATA PHARMA - ACTIVELY PREPARING FOR COMMERCIAL LAUNCH OF BARDOXOLONE AND OMAVELOXOLONE IN U.S..REATA PHARMACEUTICALS INC - AMENDED AGREEMENT MAKES $75 MILLION AVAILABLE TO CO UPON POSITIVE, TOPLINE DATA FROM EITHER CARDINAL STUDY OR MOXIE STUDY.REATA PHARMACEUTICALS INC - OVERALL, TERM LOAN FACILITY INCREASED BY $30 MILLION, FROM $125 MILLION TO $155 MILLION.  Full Article

Reata Pharmaceuticals Reports Q1 Results
Thursday, 9 May 2019 

May 9 (Reuters) - Reata Pharmaceuticals Inc ::REATA PHARMACEUTICALS, INC. ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS AND AN UPDATE ON DEVELOPMENT PROGRAMS.Q1 LOSS PER SHARE $0.98.Q1 EARNINGS PER SHARE ESTIMATE $-1.00 -- REFINITIV IBES DATA.FALCON PIVOTAL PHASE 3 TRIAL TO INITIATE IN MAY 2019.AT MARCH 31, 2019, CO HAD $313.1 MILLION IN CASH AND CASH EQUIVALENTS.  Full Article

Reata Pharmaceuticals Q4 Loss Per Share $0.86
Thursday, 28 Feb 2019 

Feb 28 (Reuters) - Reata Pharmaceuticals Inc ::Q4 LOSS PER SHARE $0.86.Q4 EARNINGS PER SHARE ESTIMATE $-1.07 -- REFINITIV IBES DATA.FALCON PIVOTAL PHASE 3 TRIAL TO INITIATE IN MID-2019.INCREASE IN NET LOSS FOR THREE-MONTH PERIOD IS PRIMARILY DRIVEN BY BOTH AN INCREASE IN EXPENSES AND A DECREASE IN REVENUE.EXPECT OUR CURRENT CASH TO FUND OUR OPERATIONS THROUGH DATA READOUTS FOR OUR THREE ONGOING REGISTRATIONAL CLINICAL TRIALS.  Full Article

Reata Pharmaceuticals Announces Positive Phase 2 Data For Bardoxolone Methyl
Wednesday, 20 Feb 2019 

Feb 20 (Reuters) - Reata Pharmaceuticals Inc ::REATA ANNOUNCES POSITIVE PHASE 2 DATA FOR BARDOXOLONE METHYL IN PATIENTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND IN PATIENTS FROM ALL FOUR COHORTS OF PHOENIX.REATA PHARMACEUTICALS INC -.REATA PHARMACEUTICALS INC - BARDOXOLONE METHYL SIGNIFICANTLY IMPROVED KIDNEY FUNCTION IN PATIENTS FROM ALL FOUR COHORTS OF PHOENIX.REATA PHARMACEUTICALS INC - BARDOXOLONE METHYL SIGNIFICANTLY REDUCED BLOOD PRESSURE AND WAS WELL-TOLERATED IN PATIENTS FROM ALL FOUR COHORTS OF PHOENIX.  Full Article

Reata Pharmaceuticals Q3 Loss Per Share $1.07
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Reata Pharmaceuticals Inc ::REATA PHARMACEUTICALS, INC. ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND AN UPDATE ON DEVELOPMENT PROGRAMS.Q3 LOSS PER SHARE $1.07.Q3 EARNINGS PER SHARE VIEW $-0.79 -- THOMSON REUTERS I/B/E/S.QTRLY TOTAL COLLABORATION REVENUE $5.2 MILLION VERSUS $12.6 MILLION.Q3 REVENUE VIEW $9.2 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Reata gets orphan drug designation from European Commission for Bardoxolone Methyl
Friday, 1 Jun 2018 

May 31 (Reuters) - Reata Pharmaceuticals Inc ::REATA ANNOUNCES ORPHAN DRUG DESIGNATION FROM THE EUROPEAN COMMISSION FOR BARDOXOLONE METHYL FOR THE TREATMENT OF ALPORT SYNDROME.REATA PHARMACEUTICALS INC - EUROPEAN COMMISSION GRANTED ORPHAN DRUG DESIGNATION FOR BARDOXOLONE METHYL (BARDOXOLONE) FOR TREATMENT OF ALPORT SYNDROME.  Full Article

Reata Pharmaceuticals Inc. Announces Q4 Loss Per Share $0.64
Friday, 2 Mar 2018 

March 2 (Reuters) - Reata Pharmaceuticals Inc ::REATA PHARMACEUTICALS, INC. ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL AND OPERATING RESULTS.Q4 LOSS PER SHARE $0.64.AS OF DECEMBER 31, 2017, COMPANY HAD $129.8 MILLION IN CASH AND CASH EQUIVALENTS.REATA PHARMACEUTICALS- BELIEVE EXISTING CASH AND CASH EQUIVALENTS, AVAILABLE DEBT AND EXPECTED MILESTONE WILL BE SUFFICIENT TO FUND INTO H2 2019.  Full Article

Reata Pharmaceuticals- Entered Third Supplement To Exclusive License & Supply Agreement With Kyowa Hakko
Friday, 8 Dec 2017 

Dec 7 (Reuters) - Kyowa Hakko Kirin Co Ltd <4151.T>::REATA PHARMACEUTICALS-ON DEC 7 CO ENTERED THIRD SUPPLEMENT TO EXCLUSIVE LICENSE & SUPPLY AGREEMENT, BY & BETWEEN CO, KYOWA HAKKO KIRIN CO LTD (KHK).REATA SAYS THIRD SUPPLEMENT ALLOWS CO TO BEGIN PORTION OF PHASE 3 CLINICAL STUDY OF RTA 402 IN FIELD OF ALPORT SYNDROME IN JAPAN - SEC FILING.REATA PHARMACEUTICALS - ON DEC 7 CO ENTERED FOURTH SUPPLEMENT TO EXCLUSIVE LICENSE & SUPPLY AGREEMENT, BY & BETWEEN CO & KHK.  Full Article

Reata Pharmaceuticals files for offering of up to $50.0 million of shares of Class A common stock‍​
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Reata Pharmaceuticals Inc ::Files for offering of up to $50.0 million of shares of Class A common stock‍​ - SEC filing.  Full Article

Reata Pharmaceuticals Q3 loss per share $0.50
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Reata Pharmaceuticals Inc :Reata Pharmaceuticals Inc announces third quarter 2017 financial and operating results.Q3 loss per share $0.50.Q3 earnings per share view $-0.41 -- Thomson Reuters I/B/E/S.Reata Pharmaceuticals Inc - qtrly ‍total collaboration revenue $12.6 million versus $12.6 million.Reata Pharmaceuticals Inc - ‍as of September 30, 2017, company had $154.6 million in cash and cash equivalents​.  Full Article